Voyager Therapeutics, Inc.
VYGRAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Mar 12, 2025 | Wells Fargo | Yanan Zhu | $10.00(+163%) | $3.81 | TheFly |
| Nov 13, 2024 | Oppenheimer | Jay Olson | $18.00(+160%) | $6.92 | StreetInsider |
| Sep 25, 2024 | Robert W. Baird | Jack Allen | $18.00(+198%) | $6.04 | StreetInsider |
| May 14, 2024 | Wedbush | Laura Chico | $8.00(-6%) | $8.48 | StreetInsider |
| Jan 2, 2024 | Wells Fargo | Jim Birchenough | $14.00(+56%) | $9.00 | StreetInsider |
| May 10, 2023 | Truist Financial | Joon Lee | $18.00(+82%) | $9.88 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 17, 2026 |
| HC Wainwright & Co. | maintain | Buy | Nov 12, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 15, 2025 |
| Wedbush | maintain | Outperform | Aug 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 8, 2025 |
| Canaccord Genuity | maintain | Buy | Mar 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 13, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Mar 12, 2025 |
| Wedbush | maintain | Outperform | Mar 12, 2025 |
| Wells Fargo | maintain | Overweight | Mar 12, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 3, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 27, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 14, 2024 |
| Canaccord Genuity | maintain | Buy | Nov 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 24, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 20, 2024 |
| Wedbush | maintain | Neutral | Aug 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 31, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 16, 2024 |
| Oppenheimer | maintain | Outperform | May 15, 2024 |
| Wedbush | maintain | Neutral | May 14, 2024 |
| Wells Fargo | upgrade | Equal Weight →Overweight | Jan 2, 2024 |
| Oppenheimer | maintain | Outperform | Aug 7, 2023 |
| Truist Securities | maintain | Buy | May 10, 2023 |
Earnings History
Next report: Mar 8, 2027 · EPS est. $-0.34| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.40 | $-0.41 | $4.0M | $6.3M |
| Aug 6, 2026 | $-0.40 | $-0.48 | $3.2M | $4.5M |
| May 7, 2026 | $-0.47 | $-0.54 | $2.6M | $8.8M |
| Mar 9, 2026 | $-0.46 | $-0.54 | $15.3M | $10.5M |
| Nov 10, 2025 | $-0.47 | $-0.53 | $13.4M | $10.5M |
| Aug 6, 2025 | $-0.57 | $-0.48 | $5.2M | $7.9M |
| May 6, 2025 | $-0.53 | $-0.35 | $6.5M | $13.9M |
| Mar 11, 2025 | $-0.59 | $-0.35 | $6.3M | $12.9M |
News
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.47 per share a year ago.
LEXINGTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced two poster presentations at the upcoming 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference taking place in Boston, November 16-19, 2026. The poster presentations will highlight VY1706, Voyager's investigational gene therapy designed to lower tau production in the brain, and VY7523, the C…
Voyager Therapeutics, Inc. remains a Strong Buy, driven by dual anti-tau programs targeting Alzheimer's Disease with key catalysts in late 2026 and 2027. Company expects phase 1b PET imaging efficacy data for VY7523 in Q4 2026 and first-in-human dosing of gene therapy VY1706 for AD in the same quarter. Strategic partnerships with Novartis, Neurocrine, and AstraZeneca have secured $500M+ in non-dilutive funding and potential $6.8B in milestones, supporting cash runway into 2028.
- Robin Swartz, Voyager's Chief Business and Operating Officer, appointed President, effective immediately; expected to succeed Alfred W. Sandrock, Jr., M.D.
Shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR - Get Free Report) crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $3.08 and traded as low as $2.25. Voyager Therapeutics shares last traded at $2.27, with a volume of 967,005 shares trading hands. Analysts Set New
Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability. Valuation and Earnings This table compares Tonix
Aligos Therapeutics (NASDAQ: ALGS - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. Institutional and Insider Ownership 60.4% of Aligos
Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
BlackRock Inc. acquired a new position in shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) in the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 5,172,063 shares of the company's stock, valued at approximately $18,102,000. BlackRock Inc. owned about 8.56% of Voyager Therapeutics at the end of the
LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Fireside chat at 3:45 p.m.
Dimensional Fund Advisors LP decreased its position in Voyager Therapeutics, Inc. (NASDAQ: VYGR) by 19.3% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 875,568 shares of the company's stock after selling 208,931 shares during the period. Dimensional Fund Advisors LP owned